Skip to content
2000
Volume 12, Issue 5
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Acute myeloid leukemia (AML) is a challenging disease to treat with the majority of patients dying from their illness. While overall survival has been markedly prolonged in acute promyelocytic leukemia (APL), survival in younger adults with other subtypes of AML has only modestly improved over the last twenty years. Physicians who treat AML eagerly await drugs like Imatinib for chronic myeloid leukemia, Cladribine for hairy cell leukemia, and Rituximab for non-Hodgkin Lymphoma which have had an important impact on improving outcome. Recent research efforts have focused on refining traditional chemotherapeutic agents to make them more active in AML, targeting specific genetic mutations in myeloid leukemia cells, and utilizing novel agents such as Lenalidomide that have shown activity in other hematologic malignancies. Here, we focus on reviewing the recent literature on agents that may assume a role in clinical practice for patients with AML over the next five years.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/156800912800673248
2012-06-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/ccdt/10.2174/156800912800673248
Loading

  • Article Type:
    Research Article
Keyword(s): Acute Myeloid Leukemia; emerging agents; novel drugs
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test